6505--Simvastatin Tablets (VA-26-00009813)
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NAC PHARMACEUTICALS (36E797)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36E79725R0066
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents1
This procurement notice announces the award of a contract for the supply of Simvastatin Tablets, as indicated by the title "6505--Simvastatin Tablets (VA-26-00009813)." The contract is managed under procurement identifier 36E79725R0066 and falls within the North American Industry Classification System (NAICS) code 325412, which pertains to Pharmaceutical Preparation Manufacturing. This classification underscores the requirement for a contractor with capabilities in the manufacturing and supply of pharmaceutical products, specifically those aligned with the needs of federal healthcare systems.
The contracting entity responsible for this award is NAC Pharmaceuticals, operating under the Department of Veterans Affairs (VA), with the office designation 36E797. The VA is a federal agency dedicated to providing comprehensive healthcare services to U.S. veterans, and this procurement supports its mission by ensuring a reliable supply of essential medications. The Product Service Code (PSC) associated with this notice is 6505, further specifying the focus on drugs and biologicals.
The primary objective of this procurement is to secure a consistent and compliant supply of Simvastatin Tablets, a medication widely used to manage cholesterol levels and reduce the risk of cardiovascular events. The intended outcome is to maintain uninterrupted access to this critical pharmaceutical for VA healthcare facilities, thereby supporting the health and well-being of veteran patients.
Key requirements for this contract likely include adherence to stringent pharmaceutical manufacturing standards, compliance with all applicable federal regulations, and the ability to deliver products that meet the VA’s quality and safety specifications. While the notice does not detail specific deliverables or quantities, contractors should anticipate the need for robust quality assurance processes, reliable distribution capabilities, and the capacity to respond to the VA’s ordering and inventory management systems.
The notice is currently active and was posted on October 3, 2026. Interested parties seeking further information or clarification are directed to contact Billy Fong, the primary point of contact for this procurement, via email at [email protected] or by phone at 708-786-4992. Additional details and any associated attachments can be accessed through the official SAM.gov opportunity listing at https://sam.gov/opp/15f64c5367df41e79739acd7509eb15d/view.
This procurement is classified as an award notice, indicating that the contract has already been awarded. There is no information provided regarding set-aside requirements or special considerations such as small business preferences. Contractors evaluating similar opportunities in the future should note the VA’s emphasis on regulatory compliance, product quality, and the ability to support large-scale, ongoing pharmaceutical supply needs.
Overall, this notice reflects the VA’s ongoing commitment to partnering with qualified pharmaceutical manufacturers to ensure the availability of essential medications for the veteran population, with a focus on reliability, safety, and regulatory adherence throughout the contract lifecycle.